中国医学科学院北京协和医学院医药生物技术研究所（以下简称药生所）创建于1958年，原名抗菌素研究所，前身可追溯到北洋政府时期的北平天坛中央防疫处，是中国抗生素的发源地和摇篮。自成功研发第一支青霉素以来，迄今已完成了临床各大类几十种抗生素的研发，占国产抗生素50%以上，为我国抗生素的研发、人才培养及产业发展起到了奠基作用，在国家感染性疾病控制中做出了突出贡献。
药生所的重点领域与特色专业是抗感染药物、微生物药物与生物技术药物研究，在国内一直保持相关学科和领域的研究优势。建所六十多年来，已获新药证书及药品注册批件70余件，国内外授权专利300余项，100多项科技成果获国家及省部级奖励，累计发表科研论文3000余篇。
药生所现有职工300余人，包括中国工程院院士2名及多名国家杰青和优青、新世纪百千万国家级人选、“万人计划”科技创新领军人才、国家和部委突贡专家、国务院政府特殊津贴专家等，已汇聚和造就了一支高水平科技创新队伍。
药生所的“微生物与生化药学”于2001年被评为教育部高等学校国内该专业领域的唯一二级重点学科，是北京协和医学院“药学”国家一级重点学科的重要组成部分。自1961年开始招生以来，迄今已培养硕、博士研究生近千名，多人获得“全国优秀博士学位论文”、“优秀青年学者奖”等奖项，为我国药学领域输送了大批优秀人才。
药生所已建成了综合的新药研究体系，并在抗感染及微生物药物领域形成优势地位。在新冠肺炎疫情防控科技攻关中，药生所充分发挥自身特色优势，通过合作研究将自主创新药物可利霉素等三个品种推向临床研究，并在基础研究中取得了重要发现，为疫情防控提供了强有力的支撑作用。另外，研究所在抗代谢综合征、抗心血管系统疾病及生物技术药物领域的布局也较为完整，在相关的基础研究及新药研发方面均取得了重要进展。
药生所将始终坚持“四个面向”，聚焦抗感染药物研发核心目标，大力加强创新队伍建设，提升在前沿交叉与共性关键技术领域的创新能力，积极推进特色药学科技创新核心基地建设，为我国卫生健康科技事业发展做出更大贡献。
Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College (HEREINAFTER referred to as INSTITUTE of Antibiotics) was founded in 1958. Its predecessor can be traced back to The Tiantan Central Epidemic Prevention Department in Peiping during the Beiyang Government period, and it is the cradle and cradle of antibiotics in China. Since the successful research and development of the first penicillin, it has completed the research and development of dozens of clinical antibiotics, accounting for more than 50% of domestic antibiotics. It has laid a foundation for China's antibiotic research and development, talent training and industrial development, and made outstanding contributions to the national infectious disease control.
The key fields and specialty of the institute are anti-infective drugs, microbial drugs and biotechnology drugs, and it has always maintained its research advantages in related disciplines and fields in China. More than 60 years since its establishment, the institute has obtained more than 70 new drug certificates and drug registration approvals, more than 300 domestic and foreign authorized patents, more than 100 scientific and technological achievements won national and provincial awards, and published more than 3000 scientific research papers.
Medicine gave birth to the existing staff of more than 300 people, including two Chinese Academy of Engineering and a number of countries and all the best green, millions in the new century national candidate, "ten thousand plan" science and technology innovation talents, tu gong expert the and ministries and commissions of the state, the State Council special government allowances, etc., have been gathered and made a high level of science and technology innovation team.
"Microbial and biochemical pharmacy" of the Institute was awarded as the only second-level key discipline in this field of higher education by the Ministry of Education in China in 2001, and is an important part of the first-level national key discipline of "pharmacy" of Peking Union Medical College. Since the beginning of enrollment in 1961, it has trained nearly 1,000 master's and doctoral students, many of whom have won the "National Excellent Doctoral dissertation", "Outstanding Young Scholar Award" and other awards, conveying a large number of outstanding talents in the field of pharmacy in China.
The institute has established a comprehensive new drug research system, and has formed a dominant position in the field of anti-infection and microbial drugs. In tackling key scientific and technological challenges in COVID-19 prevention and control, THE Institute has made full use of its own characteristics and advantages to promote the clinical research of three independently innovative drugs, including colithromycin, through cooperative research, and made important discoveries in basic research, providing strong support for epidemic prevention and control. In addition, the institute has a relatively complete layout in the field of anti-metabolic syndrome, anti-cardiovascular diseases and biotechnology drugs, and has made important progress in related basic research and new drug development.
Medicine students will always adhere to the "four dimensions", focusing on the core target anti-infection drugs, strengthen innovation team construction, improve the front cross and common key technologies in the field of innovation ability, actively pushing forward the construction of the core features of pharmaceutical science and technology innovation base for our country to make greater contribution to the development of health technology.